Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 10,946

Document Document Title
WO/2021/066059A1
This compound is represented by general formula (1), where D is a group represented by general formula (11), general formula (12), or general formula (13), at least one D is a group represented by general formula (12) or general formula ...  
WO/2021/065898A1
Provided are: an azepan derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof (in the formula: R1 represents a hydrogen atom, a C1-6 alkyl group which may have a substituent, etc.; R2 and R3 are the...  
WO/2021/065980A1
Provided is a BET degrader. A BET degrader including a compound represented by formula (I) or a pharmaceutically acceptable salt thereof is used. (In the formula, L1 and L2 are the same or different and represent a low molecular ligand f...  
WO/2021/066123A1
Provided is a novel metal complex which can be used as an electron transporting material. Metal complexes respectively represented by formulae (1) to (3). RA1 to RA9, RC1 to RC8 and RE1 to RE6 independently represent a single bond, an al...  
WO/2021/063335A1
The present application provides a compound represented by formula (I), or isomer or pharmaceutically acceptable salt thereof, and use thereof in the preparation of an ERK1/2-mediated disease drug.  
WO/2021/065374A1
The present invention improves heat resistance. A photoelectric conversion element 10 which includes a positive electrode 12, a negative electrode and an active layer 14 provided between said positive and negative electrodes, wherein t...  
WO/2021/067606A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of SMARCA2 or BRM (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a ligand...  
WO/2021/067217A1
The present disclosure is directed to compounds of Formula (I): which modulate PD-1/PD-L1 protein/protein interaction, compositions, and methods of treating various diseases, including infectious diseases and cancer.  
WO/2021/060453A1
The present invention pertains to a compound represented by formula (1a) [in the formula: p represents 1 or 2; R1 to R4 represent a hydrogen atom, etc.; ring A represents a cycloalkylene, etc.; L represents a single bond, etc.; and R rep...  
WO/2021/060042A1
The purpose of the present invention is to provide: a compound that, when being formed into a film, provides excellent reproducibility of carrier mobility regardless of the film-forming method; a composition containing the compound; a fi...  
WO/2021/057963A1
Provided are an RET inhibitor, a pharmaceutical composition comprising same and a use thereof. Specifically, the present invention relates to a compound as shown in formula (I) or a stereoisomer, geometrical isomer, tautomer, nitrogen ox...  
WO/2021/062238A1
This disclosure relates to methods and compositions for treating sickle cell anemia or thalassemia in a subject in need thereof. As described herein in a first aspect the present disclosure provides a method of treating an inherited bloo...  
WO/2021/055538A1
Provided herein are compounds and pharmaceutical compositions comprising a therapeutically effective amount of such compounds, or pharmaceutically acceptable salts, and a pharmaceutically acceptable excipient, and methods of treating neu...  
WO/2021/051899A1
The present invention provides a cyano-substituted cyclic hydrazine derivative, comprising: a compound represented by the following structural formula or a stereoisomer, a geometric isomer, a tautomer, a racemate, a hydrate, a solvate, a...  
WO/2021/055589A1
The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.  
WO/2021/032004A9
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...  
WO/2021/053046A1
The present invention relates to compounds of formula (I), to processes for preparing the compounds, and to electronic devices containing one or more of the compounds.  
WO/2021/050059A1
The present disclosure relates to DNA-PK inhibiting compounds and prodrugs thereof that are useful in the treatment of diseases, including cancer. In particular, the compounds sensitise cancers to therapies such as chemotherapy and radio...  
WO/2021/047547A1
The present invention provides a novel tricyclic aromatic heterocyclic compound, a preparation method therefor, a pharmaceutical composition and an application thereof. Specifically, the present invention provides a compound as represent...  
WO/2021/047556A1
Provided are a nitrogen-containing heterocyclic compound, and a preparation method therefor, a pharmaceutical composition comprising same and the use thereof. Specifically, provided in the present invention is a compound as shown in form...  
WO/2021/047584A1
Provided are certain TRK inhibitors, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2021/047555A1
Provided are the preparation of an aromatic heterocyclic derivative as an immunomodulator and an application thereof. Specifically, provided is a compound represented by formula I below, or an optical isomer, hydrate, solvate, or pharmac...  
WO/2021/043850A1
The present invention relates to compounds of formula (1) or (2), wherein R1 and R3 are purine or a purine analog and R2 and R4 are a small functional group. The invention also relates to intermediates of the synthesis of compounds of fo...  
WO/2021/042890A1
A heterocyclic compound shown in formula I and application thereof as a Trk kinase inhibitor.  
WO/2021/041861A1
Provided herein are N-(2-aminophenyl)-prop-2-enamide derivatives, such as those of Formula (I), methods for the synthesis thereof, and uses thereof in the treatment of cancer, such as SALL4-expressing cancer, in a cell or subject in need...  
WO/2021/039961A1
Provided are a ring-fused pyrazole derivative, which is useful as a therapeutic agent and/or a preventive agent for diseases associated with Nav1. 1 and various central nervous system diseases, and/or a pharmaceutically acceptable salt t...  
WO/2020/263980A8
This invention relates to Imidazo[l,2-a]pyridinyl Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. ...  
WO/2021/032323A1
The present invention discloses compounds according to Formula I, wherein A, B, R1, R2, and Cy are as defined herein. The present invention relates to compounds inhibiting autotaxin (NPP2 or ENPP2), methods for their production, pharmace...  
WO/2021/032004A1
Disclosed in the present invention are an azaheteroaryl compound, a pharmaceutically acceptable salt thereof, and a solvate thereof. The present invention also provides a method for preparing said compound, a composition containing said ...  
WO/2021/028382A1
The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful f...  
WO/2021/027943A1
A pyrimidinopyridazinone derivative and a medical use thereof. The derivative has a structure represented by general formula (I). The present invention also relates to a preparation method for the compound of general formula (I), a pharm...  
WO/2021/030142A1
The present disclosure relates generally to compounds that bind to Acetyl-CoA Carboxylase (ACC) and act as inhibitors of ACC. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatmen...  
WO/2020/259724A3
Disclosed in the present invention are a pyrazolone and pyrimidine compound, and a preparation method and a use therefor. Provided in the present invention is a pyrazolone and pyrimidine compound as in formula (I), said compound having b...  
WO/2021/027172A1
Disclosed is a hole transport material with a structural general formula of (A), wherein group R is any one of a carbazole group and a derivative group thereof, a diphenylamine group and a derivative group thereof, a phenoxazine group an...  
WO/2021/028854A1
The present invention provides a compound of Formula (I): (I) or an enantiomer, an enantiomeric mixture, or a pharmaceutically acceptable salt thereof; wherein the variables are as defined herein. The present invention further provides p...  
WO/2021/027911A1
The present invention relates to a spirocyclic compound and a preparation method therefor and use thereof, in particular to a compound represented by formula (1) and a preparation method therefor, and use of the compound of formula (1) a...  
WO/2021/023209A1
The present invention relates to the field of medicinal chemistry, and relates in particular to nitrogen-containing polycyclic fused ring compounds represented by formula I, and a pharmaceutical composition thereof, a preparation method ...  
WO/2021/024039A1
Provided herein are (e.g., controlled release) compositions for the treatment of acute or chronic diseases or disorders. Described herein are processable opioid conjugates. Also described herein are compositions and methods for the treat...  
WO/2021/023204A1
Disclosed is a use of a CDK4/6 inhibitor in combination with a multi-target tyrosine kinase inhibitor in preparing a medicament for treating a tumor. Specifically, the CDK4/6 inhibitor is a compound represented by formula (I) or a pharma...  
WO/2021/018287A1
Provided is a compound with inhibitory activity on SHP2, a preparation method therefor, and a use thereof. Specifically, provided is a compound represented by formula (I), a pharmaceutically acceptable salt thereof, a solvate, an isotopi...  
WO/2021/017069A1
Disclosed are a pyrrolopyrazole derivative, a preparation method therefor, and an application thereof in medicine. Specifically, the present invention relates to a class of pyrrolopyrazole derivatives represented by general formula (I), ...  
WO/2021/017114A1
A cyclic compound and a use thereof, and an electronic device. The cyclic compound comprises at least compounds represented by formulas 001-011, the cyclic compound has good thermal stability and has a matching LUMO energy level to an ad...  
WO/2021/020363A1
Provided is a compound which has a glucosylceramide synthase-inhibiting activity and is expected to be useful as a prophylactic or therapeutic agent for a lysosomal storage disease (e.g., Gaucher disease, Fabry disease, GM1-gangliosidosi...  
WO/2021/021775A1
The present disclosure encompasses solid state forms of Risdiplam, including crystalline polymorphs of Risdiplam, processes for preparation thereof, and pharmaceutical compositions thereof.  
WO/2020/263967A8
This invention relates to 2H-indazole Derivatives of formula (I'), or pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, capable of modulating the activity of IRAK4. The inventio...  
WO/2021/014365A1
Disclosed are macrocyclic compounds having the general Formula (I) or (II) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, hydrates, solvates and prodrugs thereof, and their combination with suitable medicam...  
WO/2021/011913A1
The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand whi...  
WO/2021/008455A1
Provided are an RET selective inhibitor, a preparation method therefor and a use thereof. Provided are a compound of formula (I) and a pharmaceutically acceptable salt, a solvent, a polymorph or an isomer thereof, a pharmaceutical compos...  
WO/2021/007882A1
The present invention relates to an organic compound of a nitrogen-containing heterocycle, and an organic electroluminescent device. The structural general formula of the organic compound of the nitrogen-containing heterocycle is shown i...  
WO/2021/009212A1
The invention relates to compounds of Formula I which are useful as antibacterial agents in medicine.  

Matches 1 - 50 out of 10,946